Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889343 | 0.92 | MTNR1A (0.45) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL4217159 | 0.81 | MTNR1A (0.73) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8960011 | 0.79 | MTNR1A (0.52) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL9781783 | 0.78 | CA1 (0.58) | MTNR1AMTNR1BCA1CA2ACHE | |
| Hydrochloric Acid SCHEMBL9352093 | 0.77 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL4216627 | 0.76 | CYP1A2 (0.57) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL4656341 | 0.76 | CYP1A2 (0.57) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL4207460 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL5197648 | 0.76 | CA1 (0.46) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3442063 | 0.76 | MTNR1A (0.46) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200078356-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078356-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SMN1; SMN2, CLN6 | MTNR1A 82/4885MTNR1B 70/4885CA1 1614/4885 |
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | PARK7, SMN1; SMN2, CLN6 | MTNR1A 82/4885MTNR1B 70/4885CA1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.